Question
A 40-year-old diabetic man came to medicine O.P with fever, shortness of breath. His family members also give history of fever and sore throat. His oxygen saturation was low and chest x-ray showed diffuse infiltration (
- (a) What is the most likely clinical diagnosis. ( 1 mark(s)
- (b) Name the two common viral agents for this condition. ( 2 mark(s)
- (c) Pathogenesis of the condition which caused the pandemic in 2020 ( 2 mark(s)
- (d) Name the vaccines developed against it, licensed for use in India and describe in detail any one of them. (e) List the samples collected and the tests available for diagnosis of acute condition. (f) Name one oral drug licensed for use in this condition. 6 mark(s)
Answer
(a) Most likely clinical diagnosis: Viral pneumonia/acute respiratory distress, most consistent with COVID-19 (SARS-CoV-2 infection) — a diabetic patient (a recognized risk factor for severe disease) with fever, shortness of breath, hypoxia, and diffuse chest X-ray infiltrates, with a household cluster of fever/sore throat, is the classical presentation.
(b) Two common viral agents for this condition (viral pneumonia): SARS-CoV-2 and Influenza virus (both can cause a similar clinical picture of fever, respiratory symptoms, and diffuse pulmonary infiltrates, particularly in high-risk individuals such as diabetics).
(c) Pathogenesis of the 2020 pandemic-causing condition (COVID-19/SARS-CoV-2): SARS-CoV-2 enters host respiratory epithelial cells by binding its spike (S) protein to the ACE2 receptor (with TMPRSS2-mediated proteolytic priming facilitating cell entry). Viral replication in the respiratory tract causes direct cytopathic damage to alveolar epithelium and, in more severe cases, triggers a dysregulated, excessive host immune/inflammatory response (“cytokine storm”), with massive release of pro-inflammatory cytokines (IL-6, TNF-α, IL-1) — this drives diffuse alveolar damage, increased vascular permeability, and progression to Acute Respiratory Distress Syndrome (ARDS), accounting for the diffuse infiltrates and hypoxia seen in this patient. Endothelial injury and a pro-thrombotic state also contribute to complications in severe disease.
(d) Vaccines developed and licensed for use in India (COVID-19 vaccines): Covishield (Oxford-AstraZeneca viral vector vaccine, manufactured by Serum Institute of India), Covaxin (Bharat Biotech, indigenous whole-virion inactivated vaccine), and mRNA-based/other platforms used elsewhere globally.
Detail on one — Covaxin (BBV152): an inactivated whole-virion vaccine, produced by growing SARS-CoV-2 in Vero cell culture and then chemically inactivating the virus (rendering it non-infectious while preserving its structural antigens, including the spike protein), combined with an adjuvant (Algel-IMDG) to enhance immunogenicity. Administered as a two-dose intramuscular schedule, typically 4 weeks apart. Being a whole-virion inactivated vaccine, it presents the full complement of viral antigens to the immune system (not just the spike protein alone, as with some other platforms), and does not carry the theoretical risks associated with live/vector-based vaccines, making it broadly usable across various populations.
(e) Samples and tests for diagnosis of the acute condition: Nasopharyngeal and oropharyngeal swabs (the standard specimens); tests include RT-PCR (the gold-standard confirmatory test, detecting viral RNA), Rapid Antigen Test (RAT) (faster but less sensitive, useful for point-of-care screening), and, in some settings, CBNAAT/TrueNat platforms adapted for SARS-CoV-2 detection.
(f) One oral drug licensed for use in this condition: Molnupiravir (an oral antiviral, an alternative example being Paxlovid/Nirmatrelvir-Ritonavir, licensed in various jurisdictions for early-stage/high-risk COVID-19 patients to reduce progression to severe disease).